A prominent example is the class of GLP-1 receptor agonists, which resolve NASH in a significant proportion of patients—likely through combined weight-reduction and anti-inflammatory actions—thereby linking gut–pancreas incretin signaling with gut–liver metabolic benefits [160]. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.